Opticon's catheter shows promise in pilot study:
This article was originally published in Clinica
Executive Summary
Opticon Medical's valved urological catheter for the short-term management of urinary retention following lower urinary tract surgery has shown promising results in a pilot clinical study. The trial, which evaluated the Dublin, Ohio-based company catheter in 42 women, indicated that "a self-controlled valved catheter is feasible, safe and appreciated by patients," said study leader, Dr Rodney Appell of the Cleveland Clinic, Ohio. Dublin, Ohio Opticon plans to meet with the FDA in September to discuss the design of a multi-centre clinical trial of the device in the US.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.